Abstract
RNA-mediated drugs are a rapidly growing class of therapeutics. Over the last five years, the list of FDA-approved RNA therapeutics has expanded owing to their unique targets and prolonged pharmacological effects. Their absorption, distribution, metabolism, and excretion (ADME) have important clinical im-plications, but their pharmacokinetic properties have not been fully understood. Most RNA therapeutics have structural modifications to prevent rapid elimination from the plasma and are administered intravenously or subcutaneously, with some exceptions, for effective distribution to target organs. Distribution of drugs into tissues depends on the addition of a moiety that can be transported to the target and RNA therapeutics show a low volume of distribution because of their molecular size and negatively-charged backbone. Nucleases metabolize RNA therapeutics to a shortened chain, but their metabolic ratio is relatively low. Therefore, most RNA therapeutics are excreted in their intact form. This review covers not only ADME features but also clinical pharmacology data of the RNA therapeutics such as drug–drug interaction or population pharmacokinetic analyses. As the market of RNA therapeutics is expected to rapidly expand, comprehensive knowledge will contribute to interpreting and evaluating the pharmacological properties.
Funder
National Research Foundation of Korea
Ministry of Health & Welfare
Research Fund of The Catholic University of Korea
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference104 articles.
1. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides;Kole;Nat. Rev. Drug Discov.,2012
2. RNAi therapeutics: Principles, prospects and challenges;Aagaard;Adv. Drug Deliv. Rev.,2007
3. RNA therapy: Rich history, various applications and unlimited future prospects;Kim;Exp. Mol. Med.,2022
4. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines;Park;Adv. Drug Deliv. Rev.,2016
5. Absorption, distribution, metabolism, and excretion of US Food and Drug Administration-approved antisense oligonucleotide drugs;Migliorati;Drug Metab. Dispos.,2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献